



022504

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

U.S. PTO
10/786483
22858

022504

Mail Stop Patent Application
 Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application
 under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **ST01024 US CNT**INVENTORS: **Jésus Benavides, et al**

**TITLE: Combination Of A CB1 Receptor Antagonist
 And Of A Product Which Activates
 Dopaminergic Neurotransmission In The Brain,
 The Pharmaceutical Compositions Comprising
 Them And Their Use In The Treatment Of
 Parkinson's Disease**

I hereby certify that this correspondence is being
 deposited with the United States Postal Service as
 Express Mail in an envelope addressed to Mail Stop
 Patent Application, Commissioner for Patents, P.O.
 Box 1450, Alexandria, VA 22313-1450, on

2-25-04

Date of Deposit

Maribel Mendez

Signature

EL964822511US

Express Mail No.

APPLICATION ELEMENTS

1. *Fee Transmittal Form (*e.g., PTO/SB/17*)
(Submit an original and a duplicate for fee processing)

2. Specification *Total Pages* **61**
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

3. Drawing(s) (*35 U.S.C. 113*) *Total Sheets*

4. Oath or Declaration *Total Pages* **2**

a. Unexecuted (original or copy)

b. Copy from a prior application (37 CFR § 1.63(d))

i. **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior
 application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Power of Attorney *Total Pages*

a. Newly executed (original or copy)

b. Copy from a prior application (37 CFR § 1.63(d))

6. Microfiche Computer Program (*Appendix*)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- Computer Readable Copy
- Paper Copy (identical to computer copy)
- Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part
of prior application no: PCT/FR02/02945, filed August 28, 2002.
Examiner _____, Group/Art Unit _____.
(The cross reference has been/will be inserted on page one of the specification).

This application claims priority of French Application No. 0111201,
filed August 29, 2001.
(The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

- Assignment Papers (*cover sheet & document(s)*)
- 37 CFR §3.73(b) Statement
(when there is an assignee)
- Verified English Translation Document (*if applicable*)
- Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- Certified Copy of Priority Document(s) **FR 0111201**
(if foreign priority is claimed)
- Other: **Application Data Sheet (4 pgs.)**

CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)

February 25, 2004

Balaram Gupta
Balaram Gupta, Reg. No. 40,009
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. ST01024 US CNT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 842.00)

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Filed Herewith
First Named Inventor	Jésus Benavides, et al
Examiner Name	
Group / Art Unit	

Attorney Docket No. ST01024 US CNT

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)			
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account				3. ADDITIONAL FEES			
Deposit Account Number		18-1982		Large Entity		Small Entity	
Deposit Account Name		Aventis Pharmaceuticals Inc.		Fee Code	Fee (\$)	Fee Code	Fee (\$)
The Commissioner is authorized to: (check all that apply) <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account							
FEE CALCULATION							
1. BASIC FILING FEE							
Large Entity		Small Entity		Fee Description			
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Paid			
1001	770	2001	375	Utility filing fee 770			
1002	340	2002	165	Design filing Fee			
1003	530	2003	260	Plant filing fee			
1004	770	2004	375	Reissue filing fee			
1005	160	2005	80	Provisional filing fee			
SUBTOTAL (1)		(\$ 770.00)					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE							
				Extra Claims	Fee from below	Fee Paid	
Total Claims	24	-20**=	4	x 18	= 72		
Independent Claims	1	- 3**=	0	x 86	= 0		
Multiple Dependent				0	= 0		
Large Entity		Small Entity		Fee Description			
Fee Code	Fee (\$)	Fee Code	Fee (\$)				
1202	18	2202	9	Claims in excess of 20			
1201	86	2201	42	Independent claims in excess of 3			
1203	290	2203	140	Multiple dependent claim, if not paid			
1204	86	2204	42	**Reissue independent claims over original patent			
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent			
SUBTOTAL (2)		(\$ 72.00)					
Other fee (specify) _____							
*Reduced by Basic Filing Fee Paid							
SUBTOTAL (3) (\$)							

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY		Complete (If applicable)		
Name (Print/Type)	Balaram Gupta, Reg. No. 40,009	Registration No. (Attorney/Agent)	40,009	Telephone (908) 231-3364
Signature	<i>Balaram Gupta</i>		Date	Feb. 25, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
Aventis Pharmaceuticals Inc. template